The Research Center for Clinical Neuroimmunology and Neuroscience Basel is pleased to share a new publication in Neurology: Neuroimmunology & Neuroinflammation exploring emerging cerebrospinal fluid (CSF) and serum biomarkers in multiple sclerosis (MS).
Led by Jens Kuhle and in collaboration with Johanna Oechtering and Sabine Schaedelin, the study systematically evaluates established biomarkers such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) alongside 21 novel candidates reflecting distinct pathophysiological processes.
Conducted in a cohort of nearly 300 individuals with MS and controls, the findings highlight strong associations of CXCL13, CXCL9, and IL-12b in CSF with early disease activity. In parallel, GFAP and MOG measured in serum emerged as promising markers for disease severity and prognosis.
These results represent an important step toward more precise, biology-driven monitoring of MS and contribute to ongoing efforts to enable personalized treatment strategies.
This work was made possible through the collaboration of patients, researchers, and partners across the Swiss Multiple Sclerosis Cohort Study and beyond.
Read the full publication:
